Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. see more

Bullboard (OTCQX:MRVFF)

View:
Comment by SIGG1on Nov 12, 2019 2:02pm

RE:Bloom Burton upgrades Nuvo to Buy on Dr Reddy’s Court Loss

can't really trust these guys and their recommendation though... They own 1% of the shares... Of course they are trying to promote the company and the stock.
Post by ValueCapon Nov 12, 2019 11:18am

Bloom Burton upgrades Nuvo to Buy on Dr Reddy’s Court Loss

https://www.bloomburton.com/research/NRI20191112.pdf
Comment by ronzon Nov 11, 2019 8:26pm

RE:United States District Court Denies Dr. Reddy's Laboratories

So all manipulation aside, this should go right back up to $2/ share like before this news came out in mid-May then... lol
Post by lscfaon Nov 11, 2019 7:47am

United States District Court Denies Dr. Reddy's Laboratories

Nuvo Pharmaceuticals™ Announces United States District Court Denies Dr. Reddy's Laboratories Motion for Summary Judgment of Nuvo's '996 and '920 VIMOVO Patents  ...more  
Comment by ValueCapon Nov 09, 2019 5:50pm

RE:Vimovo Patents

Wow! Thats huge. 
Comment by lscfaon Nov 09, 2019 10:37am

RE:Vimovo Patents

Great news.....
Post by midardon Nov 09, 2019 8:59am

Vimovo Patents

Dr. Reddy’s failed to persuade a New Jersey judge to dismiss a patent-infringement lawsuit brought by Horizon and Nuvo over a proposed copycat of Vimovo, used to treat arthritis. https://news ...more  
Comment by lscfaon Nov 05, 2019 9:47pm

RE:Q3 2019 Conference Call

Transcript link....      https://seekingalpha.com/article/4302022-nuvo-pharmaceuticals-inc-nriff-ceo-jesse-ledger-q3-2019-results-earnings-call-transcript?part=single
Post by midardon Nov 05, 2019 8:32pm

Q3 2019 Conference Call

https://www.nuvopharmaceuticals.com/wp-content/uploads/2019/10/10-31-2019_Investor-Presentation.pdf
Post by ValueCapon Nov 05, 2019 6:49pm

Resultz

Nuvo completed the tech transfer and the Varennes facility is set up to manufacture Resultz to its distributors, which adds one layer of value. The team apparently is still incentivized to sign a US ...more  
Comment by Marathon11on Nov 04, 2019 10:03pm

RE:RE:Highlight from earning call transcript

Forgot to mention bloom burton... only in Canada can they get paid for services but also then provide "analyst Coverage" by the same company. How many ways can you spell BS? What a joke.
Comment by Marathon11on Nov 04, 2019 9:51pm

RE:Highlight from earning call transcript

Well put! Other opportunities... Why has the company not mentioned their largest opportunity, Resultz in the US... Ledger sounded like Elmer Fudd when asked about it earlier this year. Resultz US ...more  
Post by midardon Nov 04, 2019 6:53pm

Highlight from earning call transcript

A generic version of Vimovo did not launch in the United States during the 3 months ended September 30, 2019. As a result, the company has accrued $1.7 million of license revenue related to its U.S ...more  
Post by lscfaon Nov 02, 2019 4:02pm

$2.50 target price

https://www.bloomburton.com/research/NRI20191101.pdf
Comment by Marathon11on Nov 01, 2019 6:06pm

RE:RE:RE:WHY the sell off

Just ignore it in the short - medium term. The so called pros have been manipulating the share price for months... since around the acquisition and probably before. The Vimovo news was the canary in ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities